Analgesia for laproscopic surgeries
Not Applicable
- Conditions
- Health Condition 1: PCS- Health Condition 2: O- Medical and Surgical
- Registration Number
- CTRI/2020/05/025138
- Lead Sponsor
- DRPSIMS RF
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
American Society of Anaesthesiologist Grade 1 &2
Exclusion Criteria
1.Patient refusal
2.Coagulopathy
3.Opioid dependent patient.
4.Patients with initial heart rate < 60 bpm
5.BMI < 18 kg/m2 or > 35 kg/m2
6.Baseline systolic BP < 100 mmHg.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie the analgesic effects of bupivacaine with dexmedetomidine versus buprenorphine in the CTRI/2020/05/025138 laparoscopic surgery trial?
How does the efficacy of ultrasound-guided TAP block with bupivacaine and dexmedetomidine compare to standard-of-care analgesia in laparoscopic surgery patients?
Which biomarkers, such as opioid receptor subtypes or alpha-2 adrenergic receptor expression, predict response to TAP block with bupivacaine and adjuvants in laparoscopic surgery analgesia?
What are the known and potential adverse events of TAP block with bupivacaine and dexmedetomidine or buprenorphine, and their management strategies in laparoscopic surgery?
How do current adjuvant trends for TAP blocks, like clonidine or fentanyl, compare to dexmedetomidine and buprenorphine in laparoscopic surgery analgesia?